Sun Pharmaceutical Industries Ltd , India’s largest drugmaker by revenue, reported a 15 percent jump in second-quarter net profit on Thursday, but slightly lagged estimates.
Net income for the quarter ended September was 15.72 billion rupees ($255.4 million), up from 13.62 billion rupees a year earlier. Analysts on average expected net income of 15.88 billion rupees, according to Thomson Reuters I/B/E/S.
Sun Pharma, which is in the process of acquiring rival drugmaker Ranbaxy Laboratories Ltd, is awaiting approval from India’s antitrust regulator for the deal.
Tata Consumer enters vending biz, hits 1,000-machine mark
Entrepreneurial bug bites top VC bosses
Indian ecommerce market to grow to $325 billion; digital economy to reach $800 billion by 2030
Companies Act tweak, IBC among MCA’s 100-day plan
